Andreas Argyrides
Stock Analyst at Oppenheimer
(4.53)
# 269
Out of 5,112 analysts
118
Total ratings
53.92%
Success rate
23.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Upgrades: Outperform | $11 → $40 | $18.90 | +111.64% | 5 | Dec 10, 2025 | |
| SVRA Savara | Maintains: Outperform | $8 → $9 | $6.11 | +47.30% | 2 | Nov 14, 2025 | |
| KROS Keros Therapeutics | Reiterates: Outperform | $23 → $27 | $20.83 | +29.62% | 9 | Nov 12, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Outperform | $77 → $115 | $67.70 | +69.87% | 2 | Oct 2, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $26 → $21 | $3.46 | +506.94% | 2 | Oct 2, 2025 | |
| BNTC Benitec Biopharma | Maintains: Outperform | $35 → $29 | $10.79 | +168.77% | 2 | Sep 16, 2025 | |
| KALA KALA BIO | Maintains: Outperform | $15 → $33 | $0.59 | +5,509.38% | 2 | Sep 11, 2025 | |
| UTHR United Therapeutics | Maintains: Outperform | $510 → $575 | $510.94 | +12.54% | 1 | Sep 5, 2025 | |
| MNKD MannKind | Maintains: Outperform | $12 → $15 | $5.97 | +151.26% | 2 | Sep 5, 2025 | |
| ABEO Abeona Therapeutics | Maintains: Outperform | $19 → $20 | $4.85 | +312.37% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $61 | $38.78 | +57.30% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 → $7 | $5.63 | +24.33% | 5 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $3 | $1.01 | +197.03% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $13 | $34.03 | -61.80% | 7 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $4 | $1.42 | +181.69% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $155 → $90 | $7.91 | +1,037.80% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $9 | $2.14 | +320.56% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $202.82 | -10.76% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $104 | $13.95 | +645.52% | 14 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $3.57 | +152.10% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $10.07 | +88.68% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $19.43 | +49.25% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $13.17 | +59.45% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $21.14 | +959.60% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $26.55 | +114.69% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $0.58 | +1,106.90% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.44 | +2,182.06% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $51.80 | +35.14% | 6 | Aug 1, 2023 |
Dyne Therapeutics
Dec 10, 2025
Upgrades: Outperform
Price Target: $11 → $40
Current: $18.90
Upside: +111.64%
Savara
Nov 14, 2025
Maintains: Outperform
Price Target: $8 → $9
Current: $6.11
Upside: +47.30%
Keros Therapeutics
Nov 12, 2025
Reiterates: Outperform
Price Target: $23 → $27
Current: $20.83
Upside: +29.62%
Monopar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $77 → $115
Current: $67.70
Upside: +69.87%
Larimar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $26 → $21
Current: $3.46
Upside: +506.94%
Benitec Biopharma
Sep 16, 2025
Maintains: Outperform
Price Target: $35 → $29
Current: $10.79
Upside: +168.77%
KALA BIO
Sep 11, 2025
Maintains: Outperform
Price Target: $15 → $33
Current: $0.59
Upside: +5,509.38%
United Therapeutics
Sep 5, 2025
Maintains: Outperform
Price Target: $510 → $575
Current: $510.94
Upside: +12.54%
MannKind
Sep 5, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $5.97
Upside: +151.26%
Abeona Therapeutics
Aug 15, 2025
Maintains: Outperform
Price Target: $19 → $20
Current: $4.85
Upside: +312.37%
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $38.78
Upside: +57.30%
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $5.63
Upside: +24.33%
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $1.01
Upside: +197.03%
May 19, 2025
Downgrades: Underperform
Price Target: $13
Current: $34.03
Upside: -61.80%
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $1.42
Upside: +181.69%
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $7.91
Upside: +1,037.80%
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $2.14
Upside: +320.56%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $202.82
Upside: -10.76%
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $13.95
Upside: +645.52%
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $3.57
Upside: +152.10%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $10.07
Upside: +88.68%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $19.43
Upside: +49.25%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $13.17
Upside: +59.45%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $21.14
Upside: +959.60%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $26.55
Upside: +114.69%
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $0.58
Upside: +1,106.90%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.44
Upside: +2,182.06%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $51.80
Upside: +35.14%